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Abstract
Arginine vasopressin (AVP) and its type-2 receptor (V2R) play an essential role in the regulation 
of salt and water homeostasis by the kidneys. V2R activation also stimulates proliferation of renal 
cell carcinoma (RCC) cell lines in vitro. The current studies investigated V2R expression and 
activity in human RCC tumors, and its role in RCC tumor growth. Examination of the cancer 
genome atlas (TCGA) database, and analysis of human RCC tumor tissue microarrays, cDNA 
arrays and tumor biopsy samples demonstrated V2R expression and activity in clear cell RCC 
(ccRCC). In vitro, V2R antagonists OPC31260 and Tolvaptan, or V2R gene silencing reduced 
wound closure and cell viability of 786-O and Caki-1 human ccRCC cell lines. Similarly in mouse 
xenograft models, Tolvaptan and OPC31260 decreased RCC tumor growth by reducing cell 
proliferation and angiogenesis, while increasing apoptosis. In contrast, the V2R agonist dDAVP 
significantly increased tumor growth. High intracellular cAMP levels and ERK1/2 activation were 
observed in human ccRCC tumors. In mouse tumors and Caki-1 cells, V2R agonists reduced 
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cAMP and ERK1/2 activation, while dDAVP treatment had the reverse effect. V2R gene silencing 
in Caki-1 cells also reduced cAMP and ERK1/2 activation. These results provide novel evidence 
for a pathogenic role of V2R signaling in ccRCC, and suggest that inhibitors of the AVP-V2R 
pathway, including the FDA approved drug Tolvaptan, could be utilized as novel ccRCC 
therapeutics.
Keywords
Vasopressin; V2R; renal cell carcinoma; OPC31260; Tolvaptan; Caki-1; 786-O; mouse xenograft; 
dDAVP; cAMP
Introduction
Renal cell carcinoma is the most common cancer of the kidneys, arising from tubular 
epithelial cells within the renal cortex. It is the eighth leading cause of cancer related 
fatalities with 15,000 deaths and 65,000 new cases detected per year in the United States [1]. 
Despite surgical, immunotherapy and chemotherapy interventions, the 5-year survival rate is 
only 8% for stage 4 RCC patients. RCCs occur in multiple histologically and genetically 
heterogeneous subtypes of which, ccRCC represents 80% of the cases of RCC [2]. ccRCC 
tumor cells are highly invasive, metastatic and resistant to radiation and chemotherapy [2]. 
Hence, a better understanding of the mechanisms that drive ccRCC pathogenesis could help 
in the development of new, and more effective therapies for ccRCC.
Arginine vasopressin (AVP) or antidiuretic hormone is produced mainly by the 
hypothalamus and released into the blood from the pituitary. To elicit its actions in target 
organs, it binds to its type-1 (V1aR and V1bR) and type-2 (V2R) G-protein coupled 
receptors (GPCRs). V2R is normally expressed in the renal collecting duct, distal tubule and 
thick ascending limb segments of renal nephrons, where it plays an essential physiological 
role in regulating water and electrolyte homeostasis [3]. However, ectopic expression of 
AVP and its receptors has been reported in breast, pancreatic, colorectal and gastrointestinal 
cancers, and small cell lung carcinoma [4, 5]. While V1R activation has been observed to 
increase tumor cell growth [6, 7], V2R agonists are generally known to have angiostatic, 
anti-proliferative and/or anti-metastatic effects in breast, lung and colorectal cancers [8–10]. 
However, in contrast to these protective roles of V2R, one study reported that V2R activation 
increased cell proliferation of ccRCC cell lines of human origin in vitro [11]. This finding is 
notable because ccRCC is thought to originate from proximal tubules [12–15], which 
normally does not express V2R [16].
While it appears that V2R activation may be pro-proliferative in cultured RCC cell lines, it is 
not known if V2R is expressed and active in human RCC tumors in vivo. It is also not 
known which RCC subtypes express V2R; if AVP-V2R cell signaling regulates RCC tumor 
growth; or if V2R is potentially a viable target for therapeutic inhibition in RCC. As such, in 
the current study, we asked whether AVP-V2R signaling is pathogenic in RCC, and tested 
the therapeutic potential of targeting V2R for inhibition in this malignancy both in vitro and 
in vivo.
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Materials and Methods
Drugs and reagents:
Tolvaptan (OPC41061, 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino) 
benzoyl]-2,3,4,5- tetrahydro-1H-1-benzazepine), OPC31260 (Mozavaptan, 5-
(Dimethylamino)-1-[4-(2-methylbenzamido)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine 
hydrochloride), 8-Br-cAMP, and dDAVP (1-desamino-8-d-arginine vasopressin) were from 
Sigma Millipore (St. Louis, MO). Primary antibodies were purchased for phosphorylated 
cAMP response element binding protein (pCREB) (#9198S), CREB (#9197S), Ki-67 
(#9449S), phosphorylated extracellular signal regulated kinase (pERK1/2) (#9101S), and 
ERK1/2 (#SC-94) from Cell Signaling Technology (Danvers, CA, USA); vascular 
endothelial growth factor (VEGF) (#SC-7269) and GAPDH (#SC-47724) from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA) and V2R (#V5514) from Sigma Millipore (St. Louis, 
MO, USA) and CD31 (#ab28364) from Abcam (Cambridge, MA, USA). Secondary 
antibodies were from Dako (Carpinteria, CA) and ECL reagent was from Perkin Elmer 
(Waltham, MA, USA).
TCGA data analysis:
TCGA data were accessed and downloaded through the Xena Genome Browser (University 
of California Santa Cruz). Subsequent analyses were conducted in R (v3.5.1) [17] using the 
car and Rmisc packages. Figures were constructed using the ggplot2 package.
Human tumor biopsy tissue:
De-identified tissues from surgically removed human ccRCC tumor samples from 8 patients, 
each of whom had pathologically proven clear cell RCC, and 8 non-malignant control 
kidney tissues were obtained from the University of Kansas Cancer Center’s Biospecimen 
Core Facility. Our protocols were approved by the Institutional Review Board (IRB).
Tumor Microarray:
TMA array (#KD2082, from US Biomax Inc. Derwood, MD) with 164 ccRCC tumor tissue 
cores, 8 papillary RCC, 10 other RCC subtypes (6 transitional, 3 chromophobe and 2 
squamous cell RCCs),10 samples each of cancer-adjacent non-malignant control and non-
malignant control kidney tissue cores (one specimen per patient). The TMA slide was 
immunostained for V2R as described below, and V2R staining intensity and immunoreactive 
areas were scored as 0 (None), 1 (Low), 2 (moderate), or 3 (high). Scoring of tissue cores 
was performed by a pathologist, blinded to the identity of samples.
Immunostaining:
Tumor tissues were fixed and immunofluorescence and immunohistochemistry staining and 
imaging were performed as described before[18].
cDNA array:
A human cDNA array (#HKRT102) consisting of cDNA from 9 control non-tumor kidney 
tissue, 27 ccRCC and 12 papillary RCC was purchased from OriGene, Rockville, MD. RT-
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PCR was carried out as following the manufacturer’s instructions, and samples were run on 
2% agarose gels.
Real-time PCR:
RNA was isolated using a Qiagen RNA isolation kit, cDNA was synthesized using a reverse 
transcription kit from Applied Biosystems, and PCR was performed on an ABI PRISM 7000 
sequence detection system (Applied Biosystems, CA). Primers are described in 
Supplemental Table 1.
Cells:
Human ccRCC cell lines 786-O (ATCC-CLR-1932), Caki-1 (ATCC-HTB46), , ACHN 
(ATCC-CLR-1611), and human renal proximal tubular HK-2 (ATCC-CLR-2190) cells were 
from American Type Culture Collection. 786-O cells were authenticated by STR profiling, 
and Caki-1 cells were tested for mycoplasma contamination.
Cell viability:
Exponentially growing cells in 24-well plates were serum deprived for 16h, following which 
the cells were incubated with 0.2%FBS- containing media with vehicle or V2R agonist or 
antagonists for 48h. The cells were then incubated in MTT solution (5 mg/mL) for 2h, 
following which the MTT solution was washed off and purple formazan solubilized in 
DMSO and quantified by spectrophotometry at 570nM. The study was replicated 3 times, 
each with n=6 samples.
Clonogenic assay.
Cells were plated (1,000 cells/well) in 6-well plates. After 16h, cells were treated with 
different doses of OPC31260. Following 48h incubation, cells were washed and grown for 
10 days until visible colonies formed. Colonies were fixed with a 1:1 ratio of acetone: 
methanol, stained with 0.25% crystal violet in 25% methanol, washed, air-dried and 
photographed. Crystal violet was dissolved in sodium citrate buffer (0.1M, 50% ethanol, pH 
4.2) and absorbance was measured at 590nM. The study was replicated 3 times, each with 
n=2 samples.
Cell cycle analysis:
Cells grown on 100mm petridishes were serum deprived for 16h to synchronize cells, 
followed by incubation in 1% FBS-containing media in the presence of vehicle or V2R 
antagonists for 24h. Cells were then trypsinized, washed twice with PBS, fixed using pre-
chilled 70% ethanol overnight, and permeabilized with PBS containing 0.1% Triton X-100, 
1 mg/ml propidium iodide (Sigma-Aldrich, MO) and 2 mg/ml DNase-free RNase at room 
temperature. Flow cytometry was performed using FACS Calibur analyzer (Becton 
Dickinson, Mountain View, CA), capturing 10,000 events for each sample. ModFit LT TM 
software (Verity Software House, Topsham, ME) was used to analyze results. The study was 
replicated 3 times, each with n=2 samples.
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Wound closure assay:
Cells were grown to confluence in 6-well plastic plates, then changed to 0.2% FBS-
containing medium for 16h. A scratch induced wound was then created using a sterile pipet 
tip. Plates were washed to remove dislodged cells and the same areas of the wounds were 
photographed at 0 hour, and after 24h of incubation in 0.2% FBS-containing medium. A 
separate set of plates with similar treatment was used to assess cell proliferation. The study 
was replicated 3 times, each with n=3 samples.
Gene silencing using siRNA:
V2R-siRNA (AVPR2-SiRNA) (4390824; Clone 1: S1842, Clone 2: S1843 ) and Scrambled 
siRNA (AM4620) were purchased from Ambion. When the cells were 30–50% confluent, 
transfections were performed using Lipofectamine® RNAiMAX (Invitrogen Carlsbad, CA) 
following the manufacturer’s instructions. For cell cycle analysis, cell viability and wound 
closure, experiments were started at 32h after transfection and continued as described.
Detection of apoptosis/necrosis using Annexin V-FITC/PI staining:
Annexin V-FITC/PI staining was performed using FITC AnnexinV apoptosis detection kit 
(BD Biosciences, USA). Similar studies to cell viability were performed. Cells incubated 
with OPC31260 for 24h were washed in cold PBS, resuspended in calcium containing 
binding buffer (10 mM HEPES, 140mM NaCl, 5mM CaCl2; pH 7.4) at 1X106 cells/ml and 
stained for 15min, with 5μl Annexin V-FITC and 5μl PI at 1 μg/ml. 10,000 cells were 
analyzed for FITC (excitation 488nm and emission 530nm) and PI (610nm) fluorescence. 
CellQuestPro® software (Becton, Dickinson, Heidelberg, Germany) was used to determine 
the percent viable (Annexin V-PI-), early apoptotic (Annexin V+PI-), late apoptotic/necrotic 
(Annexin V+PI+) and necrotic cells (Annexin V-PI+). The study was replicated 2 times, 
each with n=4 samples.
In vivo xenograft study: All animal studies were carried out according to the protocols 
approved by the University of Kansas Institutional Animal Care and Use Committee. Female 
Athymic Nude-Foxn1nu mice, ~25g and 7–8 weeks old from Envigo/Harlan were 
subcutaneously injected on the right flank region with 1×106 Caki-1 cells in 100μl of 
DMEM medium. Tumor volumes were measured with calipers following the formula, 
Tumor volume = (length x width2)/2. When tumor volumes reached ~80–100mm3, mice 
were randomized based on their tumor volumes using a randomization chart.
The mice received OPC31260 (30mg/Kg BWt), OPC31260 (60mg/Kg BWt), dDAVP 
(1μg/Kg BWt) by daily intraperitoneal injection[19–21] ; or Tolvaptan (120mg/Kg BWt in 
1% aqueous solution of hydroxypropyl methylcellulose) by daily oral gavage for 28 days. 
Vehicle group received saline (50μl/20g mouse, IP) and 1% aqueous solution of 
hydroxypropyl methylcellulose (200μl/20g mouse,oral gavage). Body weights and tumor 
volumes were measured every other day. Investigators were not blinded to the identity of the 
treatments. At the end of the study, tumors were harvested, photographed, weighed and flash 
frozen or paraffin embedded for further analysis. 8 mice were used in each group.
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Immunoblotting:
Tumors tissues or cultured cells were homogenized in SDS Laemmli buffer and 
immunoblotting was carried out as described before [22].
Measurement of cAMP:
Tumors were ground to a fine powder under liquid nitrogen and homogenized in 10 volumes 
of ice cold 0.1M HCl, and centrifuged at 600g. In cell culture studies, Caki-1 cells grown on 
6-well plastic plates were pre-treated with IBMX (50μM) for 20 minutes, followed by V1aR 
and V2R antagonists, or dDAVP (1nM [11, 23]) treatment for 10 or 30 minutes. The cells 
were then washed with ice cold PBS and lyzed in 0.1M HCl. The cAMP levels in tissue and 
cell extracts were measured as described before[18–20] using an ELISA kit (#CA-200, 
Sigma-Aldrich, MO,USA). For tumor tissues, 7 control and 8 ccRCC tumor tissue were 
used. The cell culture study was replicated 3 times, each with n=3 samples.
TUNEL assay for apoptosis:
TUNEL assays were was performed on tumor sections using In Situ Cell Death Detection 
Kit (Roche Applied Science, IN, USA) following the manufacturer’s instructions. n=8 from 
each study group.
Statistical analysis:
All statatistical analyisis was performed using GraphPad Prism, Version 5.0d. Two way 
repeated measures of analysis of variance (ANOVA) followed by the Bonferroni test , one 
way ANOVA followed by Dunnett’s multiple comparison test, or two-tailed unpaired 
student’s t-test with Welch’s correction and F test were performed. P<0.05 was considered 
significant. Data were expressed as mean ± SEM for in vivo and mean ± SD for in vitro 
studies. Sample size estimate was not performed for in vitro studies. Sample size estimate 
for in vivo studies were made using statistical analysis of power using an on-line calculator 
at https://www.stat.ubc.ca/~rollin/stats/ssize/n2.html. Sample size of 8 mice was determined 
based on power analysis, to have 95% power, to detect a 50% reduction in tumor weight 
between Vehicle treated and OPC31260 treated mice (α=0.05). Number of samples and 
study replicates are provided under each method section.
Results
Abnormal V2R expression in human tumors:
To determine the possible clinical relevance of V2R expression in cancer, we first examined 
the pan-cancer gene expression of V2R (AVPR2 gene) and its ligand, AVP, in the TCGA 
database. AVPR2 was found to be upregulated in cancers of the breast, bladder, colon, lung, 
ovary, pancreas, prostate, skin, thyroid, thymus, head and neck, and in sarcoma and diffuse 
large B-cell lymphoma, with kidney cancer being one of the major expressors (Fig-1A). 
Among the limited number of cancer types covered by the index, higher AVP gene 
expression was restricted to cancers of the kidney, adrenocortical, bladder and liver 
(Fig-1B). AVPR2 and AVP gene expression were detected in chromophobe, papillary, and 
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clear cell RCC (Supplemental-1A, B). Hence, to further examine the role of V2R in RCC, 
we next determined its expression in human RCC cell lines and tumors.
V2R mRNA expression was detected in 14 out of 27 human ccRCC tumors using a 
commercially available cDNA array, (Fig-1C), whereas only 1 out of 12 human papillary 
RCC tumors showed V2R expression (Supplemental-2A). V2R expression was also 
observed in nearly all cDNA samples that we isolated from primary human ccRCC tumor 
biopsy samples (Supplemental-2B). Although kidneys are not normally known to secrete 
AVP, many tumors are known to acquire the capacity to secrete neuropeptides [24]. Hence, 
to determine if in addition to ectopic V2R expression, ccRCC tumors can also produce its 
ligand, we examined AVP mRNA levels. AVP expression was detected in 12 out of 27 
human ccRCC tumors in the cDNA array (Fig-1C) and 2 out of 8 human ccRCC tumor 
biopsy samples (Supplemental-2C). AVP was also detected in 5 out of 12 human papillary 
RCC tumors in the cDNA array (Supplemental-2A). V1R mRNA was detected in all human 
ccRCC and papillary tumors (Supplemental-2 A,B,E).
Immunostaining to detect V2R protein expression in ccRCC tumor tissue sections showed 
cell membrane associated V2R in tumor cells, but not in the tumor stroma (Fig-1D). In the 
non-malignant control kidneys, cells of the proximal tubules did not express V2R (Fig-1D). 
In a tumor tissue microarray of RCC tumor sample cores from different patients, 156 out of 
162 ccRCC samples showed V2R expression (Fig-1E). V2R expression in ccRCC tumor 
cores also increased with increasing clinical tumor grade (Fig-1F) and TNM values 
(Fig-1G). V2R mRNA was also detected in Caki-1, 786–0 and ACHN human RCC cell lines 
(Fig-1H). V1R was found to be expressed in control HK2 cells lines, compared to which, 
Caki-1, 7860 and ACHN cell lines showed relatively lower V1R expression 
(Supplemental-2D).
V2R is normally expressed in kidney collecting ducts, distal tubules and thick ascending 
limbs, but not in proximal tubules [16]. As expected, we detected V2R mRNA in non-
malignant control kidney tissue using cDNA array (Fig-1C, Supplemental-2B) and by 
immuno-staining of tissue sections (Fig-1D, E). V2R was not detected in the HK-2 human 
proximal tubule cell line (Fig-1H), or in the proximal tubules of non-malignant control 
kidney tissues (Fig-1D). These results demonstrate that the expression of V2R and its ligand, 
AVP in human ccRCC tumors is ectopic and abnormal.
V2R antagonists inhibit growth of ccRCC cell lines in vitro:
To determine the possible role of V2R in tumor cell survival, proliferation and migration, in 
vitro studies were carried out. Treatment with the V2R antagonist OPC31260 for 48h dose-
dependently reduced cell viability of 786-O and Caki-1 cells as determined by MTT assay, 
with a 50% reduction noted at 5–10μM doses (Fig-2A). No significant change in cell 
viability was noted at 24h under similar treatment conditions. In contrast to ccRCC cells, 
control HK-2 cells had significantly higher survival (over 92%) at the same doses of 
OPC31260 (Supplemental-3A). A significant decline in colony formation was also observed 
starting at 5 and 10μM doses of OPC31260 for 786-O and Caki-1 cells respectively (Fig-2B, 
C). Cell cycle analysis revealed that 60–70% of 786-O and Caki-1 cells treated with 10μM 
or higher doses of OPC31260 were in the G2/M cell cycle phase, suggesting G2/M cell 
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cycle arrest (Fig-2D, E, F). However, OPC31260 treatment caused only a small increase in 
apoptosis in these cells (Supplemental-3B, C). OPC31260 treatment also dose-dependently 
reduced wound repair of 786-O and Caki-1 cell monolayers (Fig-2G, H). These results 
suggest that inhibition of V2R in ccRCC cells reduces clonogenicity and is cytostatic, and 
that inhibition of cell proliferation occurs by inducing G2/M cell cycle arrest rather than 
lytic death.
To further confirm the role of V2R in ccRCC cell growth, we also tested the effect of 
another V2R antagonist, Tolvaptan. Tolvaptan is a Food and Drug Administration (FDA) 
approved drug used to treat hyponatremia [25], and was recently approved to treat polycystic 
kidney disease (PKD) [26]. Caki-1 cells treated with increasing doses of Tolvaptan showed a 
significant reduction in cell viability (Fig-2I) and wound closure (Fig-2J, Supplemental-3D) 
starting at a dose of 10μM. Treatment of Caki-1 cells with dDAVP, a V2R agonist showed a 
trend towards increased cell viability and wound closure when compared to vehicle 
treatment, but the values were not significantly different (Fig-2I, J). Unlike OPC31260, 
Tolvaptan did not induce G2/M cell cycle arrest. Instead, Tolvaptan treatment at 50 and 
100μM for 24h showed 18% and 26% increases in the numbers of cells in G0/G1 (Fig-2K).
The V2R antagonist OPC31260 suppressed ccRCC tumor growth in a mouse xenograft 
model:
To determine if V2R is a therapeutic target for ccRCC, the effect of OPC31260, a V2R 
antagonist was examined. For the studies, Caki-1 cells, which express V2R (Fig-1C), were 
implanted subcutaneously in nude mice. Within 10 days, small tumors expressing V2R 
(Supplemental-4A) appeared. Mice carrying tumors of approximately 80–100mm3 size were 
randomized into three groups for treatment with vehicle, OPC31260 (30mg/Kg) or 
OPC31260 (60mg/Kg) for 28 days by daily intraperitoneal injections. Tumor volumes in the 
vehicle treatment group increased steadily, and by day 28 were 7.8-fold higher than on day 1 
(Fig-3A). In contrast, the tumor volumes in the OPC31260 treatment groups failed to even 
double in size after 28 days of treatment (Fig-3A). At sacrifice, the tumors in the OPC31260 
treatment groups were smaller and weighed significantly less than in the vehicle treatment 
group (Fig-3B, C). No significant difference in tumor volumes or weights were observed 
between the mice treated with 60 mg/Kg or 30 mg/Kg doses of OPC31260 (Fig 3A, B). 
These results suggest that V2R could play a pathogenic role in ccRCC, and that its inhibition 
can reduce tumor growth in mice. OPC31260 treatment did not significantly affect the body 
weight of the mice, but reduced urine osmolality, as expected, in a dose-dependent manner 
(Supplemental-4B, C), suggesting that OPC31260 at these doses is well tolerated, but 
inhibits the V2R-regulated urine concentrating ability in these mice.
Tolvaptan suppressed ccRCC tumor growth, while dDAVP promoted tumor growth in a 
mouse xenograft model:
To determine if Tolvaptan can be repurposed for RCC therapy, we tested its effect on tumor 
development in mice. Additionally, the effect of dDAVP, a V2R selective agonist on tumor 
development was also tested. As before, Caki-1 cells were implanted subcutaneously in nude 
mice, and following tumor growth, mice were randomized into three groups: vehicle, 
Tolvaptan (120mg/Kg by daily oral gavage) or dDAVP (1μg/Kg by daily IP injection) for 28 
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days. As in the previous study, the tumor volumes in the vehicle treatment group increased 
by 8-fold when compared to day 1 (Fig-4A), while in the Tolvaptan treatment group, tumor 
volumes increased only by 2-fold (Fig-4A). By comparison, tumor volumes in dDAVP 
treatment group significantly increased starting on day 21, and by day 28 were 14-fold 
higher than on day 1 (Fig-4A). At sacrifice, the tumors in the Tolvaptan group were smaller 
and weighed significantly less when compared to the vehicle group, while the tumors were 
significantly larger in the dDAVP group (Fig-4B, C). Tolvaptan and dDAVP treatment did 
not significantly change the body weight of the mice, but as with OPC31260 treatment, urine 
osmolality was significantly reduced by Tolvaptan treatment and increased by dDAVP 
treatment (Supplemental-5A, B), indicating that these AVP analogs were having their 
expected effects on urine concentrating ability with minimal obvious toxicity.
V2R antagonists reduced tumor cell proliferation and VEGF levels, and increased 
apoptosis in vivo:
To determine the effect of Tolvaptan and OPC31260 on tumor cell growth, we measured cell 
proliferation and apoptosis in the tumors obtained from the above in vivo studies. In both the 
OPC31260 and Tolvaptan groups, the tumors showed significantly reduced Ki-67 staining 
(Fig-5A,B), and increased TUNEL staining (Fig-5A,C) compared to vehicle treatment. In 
contrast, tumors in the dDAVP group showed a significant increase in Ki-67 staining and 
reduced TUNEL staining compared to the vehicle group (Fig-5A, B, C). Tumor microvessel 
density, determined by staining for CD31, was significantly reduced by OPC31260 
treatment and increased by dDAVP treatment (Fig-5A, D). Tolvaptan treatment did not 
appear to alter tumor microvessel density. However, OPC31260 and Tolvaptan significantly 
reduced vascular endothelial growth factor (VEGF) protein levels, an important angiogenic 
growth factor in the tumors compared to vehicle treatment (Fig-5E, F), while dDAVP did not 
affect VEGF levels. These results suggest that V2R inhibition can reduce angiogenesis and 
tumor cell proliferation, and increase apoptosis in ccRCC tumors. To further test the effect 
of V2R inhibition on VEGF expression in ccRCC cells, we treated Caki-1 cells with 
OPC31260 and Tolvaptan. VEGF protein levels were unaffected in Caki-1 cells treated for 
16h with dDAVP, but were significantly reduced by Tolvaptan and OPC31260 (Fig-5G).
V2R activity stimulates mitogenic cell signaling and cell growth in ccRCC:
To examine V2R post-receptor mechanisms in ccRCC, we examined human ccRCC tumor 
biopsy tissue samples. In ccRCC tissue, high levels of pERK1/2 (Thr202/Tyr204), ERK1/2, 
pCREB (Ser133) and CREB were observed (Fig-6A and Supplemental-6A,B), as well as 
high intracellular cAMP levels (Fig-6B). Since ERK1/2 can be regulated by multiple 
mechanisms in cancer cells, including by V1R [7], we determined the effect of V2R 
antagonists on ERK1/2 activity. In mouse xenograft tumor tissue lysates, a significant 
reduction in pERK1/2 was observed in the OPC31260 and Tolvaptan groups, compared to 
the vehicle treatment groups (Fig-6C,D,E,F). We next measured intracellular cAMP 
generation in vitro, since (unlike V1R) activation of V2R induces Gs-mediated adenylate 
cyclase stimulation resulting in increased intracellular cAMP levels and CREB activity. 
Short term treatment with dDAVP significantly increased intracellular cAMP levels in 
Caki-1 cells, while the V2R antagonists OPC31260 and Tolvaptan significantly reduced 
cAMP levels (Fig-6G). Consistently, dDAVP increased pERK1/2 and pCREB levels in 
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Caki-1 cells within 5–30 minutes after treatment (Fig-6H), while OPC31260 and Tolvaptan 
reduced the pERK1/2 and pCREB levels (Fig-6I). In this study, the V1R antagonist 
SR49059 showed no effect on pERK1/2 and pCREB levels (Fig-6I). Cyclic AMP can either 
be pro- or anti- proliferative, depending on the type of cancer. To further confirm that an 
increase in intracellular cAMP induces proliferation in ccRCC cells, we determined the 
effect of cAMP on cell proliferation using MTT assay. Caki-1 cells were treated with 
forskolin, a direct activator of adenylate cyclase, that increases intracellular cAMP, or 8-Br-
cAMP, a cell permeable cAMP analog. Both treatments significantly increased cell 
proliferation at 48h compared to vehicle treated cells (Supplemental-7).
To further confirm a role for V2R in ccRCC cell growth, we tested the effect of V2R gene 
silencing in Caki-1 cells. When compared scrambled-siRNA group, V2R-siRNA or did not 
show cell cycle arrest (Fig-6J, K), but showed significantly reduced cell viability (Fig-6L) 
and wound closure (Fig-6M). Importantly, OPC31260 treatment caused G2/M cell cycle 
arrest, reduced cell viability and wound closure in the scrambled-siRNA group, it failed to 
do so in the V2R-siRNA group (Fig-6K, L, M) consistent with the effect of OPC31260 
being through inhibition of V2R.
Discussion
The present study demonstrates a novel role of the vasopressin type 2 receptor (V2R) in 
ccRCC tumor growth. Herein, we show for the first time that V2R is abnormally expressed 
in human ccRCC tumors and plays a pathologic role in driving tumor growth. V2R 
antagonists were found to reduce cell viability, clonogenicity, and wound closure, and to 
induce cell cycle arrest of ccRCC cell lines in vitro. Moreover, V2R antagonists suppressed 
ccRCC tumor growth in a mouse RCC xenograft model by reducing tumor cell proliferation 
and increasing apoptosis, while a V2R selective agonist had the reverse effect. V2R 
inhibition was found to reduce cAMP levels, and ERK and CREB activity in ccRCC cell 
lines or mouse xenograft tumors. These studies reveal a previously undescribed role of V2R 
in the pathogenesis of ccRCC, and suggest the possibility of using V2R antagonists, 
including the FDA-approved drug Tolvaptan as a novel treatment strategy for ccRCC.
While V2R mRNA levels in the TCGA database did not correlate with ccRCC patient 
survival, our studies demonstrated that V2R is upregulated and can be implicated in the 
pathology of ccRCC. A recent report citing TCGA data demonstrated a total of 9 
significantly mutated genes in ccRCC. Mutations in the tumor suppressor PTEN correlates 
with poor survival in the majority of cancer patients. However, mutant PTEN in ccRCC 
samples in the TCGA database do not correlate with poor survival. Thus, although by far, 
mRNA levels are indicative of the role of a protein in overall survival of cancer patients, 
there are instances when they do not correlate despite a role in disease pathogenesis [27]. 
Our observation of abnormal V2R expression in human ccRCC tumors is novel, and 
consistent with a previous in vitro study which showed V2R expression in cultured ccRCC 
tumor cell lines [11]. We demonstrated V2R mRNA and protein expression in human 
primary ccRCC tumors and detected V2R expression in tumor cell membranes. It is to be 
noted that V2R is normally expressed in the collecting duct, distal tubule and thick 
ascending limb segments, but not in the proximal tubules of the renal nephrons [16]. Hence 
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V2R expression in ccRCC tumor cells, which are believed to be of proximal tubular origin 
[12–15], is ectopic, rather than simply being higher in expression when compared to non-
malignant control tissue.
We also detected AVP mRNA expression in human ccRCC tumors. Normally, AVP is 
synthesized and secreted by specialized neurosecretory cells of the hypothalamus, which 
have not been described before in normal kidneys, or in ccRCC tumors. Thus, ectopic 
expression of V2R as well as its ligand could provide a survival and growth advantage to 
ccRCC tumor cells. ‘Neuropeptide hormones and their receptors are known to be involved in 
the oncogenic transformation process in various cancers [24]. Ectopic expression of AVP 
and its receptors has been reported in prostate, colon, breast, small cell lung carcinoma, 
gastrointestinal, and head and neck cancers [28, 29]. An abnormal splice variant of V2R, 
which could negatively regulate normal V2 receptors has also been reported [29, 30]. Based 
on prior studies, the effect of AVP on tumor growth appears to be dependent on the 
following: (A) Type of cancer: AVP promotes growth of SCLC and breast cancer cell lines 
in vitro [7, 31–33]. In vivo, transgenic AVP overexpression increased mammary tumor 
growth [34], while antibody- mediated targeting of pro- vasopressin impaired SCLC and 
breast cancer tumor growth in mice [35, 36]. However, in other studies AVP had no growth 
stimulatory effects on SCLC or adreno-cortical tumor cell lines [37–39]. (B) AVP dose: AVP 
doses of 0.01–1nM were growth stimulatory, while doses above 10nM were growth 
inhibitory in MCF7 breast cancer cell lines [33]. (C) AVP receptor subtype and their post-
receptor signaling: The growth-promoting role of AVP on cancer cells is thought to be 
regulated by V1R via G proteins of the Gq family, and attributed mainly to rise a in [Ca++]i 
and pERK1/2 levels. Moreover, V1R antagonist treatment reduced AVP induced 
proliferation of breast cancer cells [4], while V1R expression in CHO cells which normally 
do not express AVP receptors increased their cell proliferation [6] [40]. Unlike V1R, V2R 
activation is generally thought to inhibit cancer cell proliferation because V2R activation 
increases intracellular cAMP levels, a known inhibitor of cell proliferation in some cancers 
[41–45]. However, cAMP is also pro-proliferative in many types of cancers, and in PKD 
through stimulation of the ERK pathway [46–52].
Our in vivo studies showed that dDAVP can stimulate increases in tumor cell proliferation 
and tumor growth, and a reduction in tumor cell apoptosis. This observation is consistent 
with an earlier in vitro study in which dDAVP increased proliferation of ccRCC cell lines, 
which could be blocked by a V2R antagonist [11]. However, dDAVP and its modified 
analogues reduce tumor metastasis, angiogenesis and cell proliferation in lung, prostate, 
breast and colorectal cancers [8–10, 53–56]. Since dDAVP has greater selectivity for V2R 
compared to V1R [57], these studies concluded that the effect of dDAVP could be via V2R, 
and protective in these cancers. Our in vitro and in vivo studies in ccRCC now show that 
V2R is growth promoting in ccRCC. While it is currently unclear as to why dDAVP’s role in 
tumor progression is different in breast cancer or small cell lung carcinoma versus ccRCC, 
the post-receptor cell signaling mechanisms could partly explain the difference.
Our studies show that intracellular cAMP and pERK1/2 levels are high in human ccRCC 
tumors, and can be increased by dDAVP and suppressed by V2R antagonists in vitro and in 
vivo. Since V1R activation does not increase cAMP, and because dDAVP, OPC31260 and 
Sinha et al. Page 11
Oncogene. Author manuscript; available in PMC 2020 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Tolvaptan are selective for V2R, cAMP mediated activation of ERK1/2 is likely to be the 
key V2R post-receptor mechanism in ccRCC. The RAS-RAF-MEK-ERK signaling cascade 
can be activated by multiple mechanisms in cancer cells [58, 59] and its inhibition can 
reduce tumor growth and angiogenesis in rodent models of RCC [60, 61]. Moreover, 
sorafenib, a multi-kinase inhibitor which inhibits RAF-1 and B-RAF, is an approved drug for 
RCC [62]. We found V1R to be expressed in all human control kidneys and ccRCC tumors. 
However, SR49059, a V1R inhibitor, failed to reduce pERK1/2 levels in Caki-1 cells, unlike 
V2R antagonists which did so. Importantly, V2R gene silencing in Caki-1 cells not only 
reduced cell viability and wound closure, but abolished the ability of OPC31260 to induce 
cell cycle arrest or further reduce cell viability and wound closure. These findings suggest 
that V2R activation can regulate ccRCC tumor growth.
V2R activation in response to AVP is a frequent and normal occurrence in some renal 
tubular segments, but it does not stimulate cell proliferation or angiogenesis. In fact, dDAVP 
suppresses cell proliferation related gene expression in normal mouse kidneys [63], because 
cAMP via PKA inhibits RAF-1, and hence the RAS-RAF-MEK-ERK signaling pathway, 
which inhibits cell proliferation [64]. The pro-proliferative and tumor growth promoting 
effects of V2R stimulation in ccRCC in our study is novel, and similar to that in PKD, a 
disease characterized by abnormal proliferation of renal tubular epithelial cells causing 
progressive growth of renal cysts. Unlike ccRCC tumors, cysts in PKD originate mainly 
from collecting ducts [18] which normally express V2R. In PKD, V2R expression, cAMP 
and pERK1/2 mediated cell signaling are enhanced in a setting of low intracellular calcium 
levels, which allows PKA activation of B-RAF, stimulating increased cell proliferation [64]. 
Similarities exist in pathogenic mechanisms in PKD and cancers in general [65], and our 
study adds another by demonstrating that a V2R, cAMP and ERK1/2 dependent mechanism 
could be common to PKD and ccRCC.
OPC31260 is about 100 times more selectivity for V2R than for V1aR [66], while Tolvaptan 
has 29-fold greater selectivity for human V2R than V1aR [67]. Moreover, Tolvaptan, a 
structural derivative of OPC31260 does not inhibit V1bR and has no intrinsic V2R agonistic 
effect [67]. In the current study OPC31260 (30mg/Kg) had a relatively better effect on 
reducing tumor size, tumor cell proliferation and microvessel density and increasing 
apoptosis compared ot Tolvaptan in vivo. OPC31260 was also more effective in causing cell 
cycle arrest, reducing cell viability and wound closure than Tolvaptan. Although Tolvaptan 
has relatively better oral activity than OPC31260 [67], it has a mean absolute bioavailability 
of 56% in humans [68]. This could be the reason for the relatively lower effect of Tolvaptan 
(oral) compared to OPC31260 (intraperitoneal) in our in vivo study. OPC31260 and 
Tolvaptan doses (30mg/Kg, and 120mg/Kg respectively) which significantly suppressed 
ccRCC tumor growth in our study are known to block are known to block AVP-dependent 
V2R activity and reduce urine osmolality in rodents [66, 69]. A dose of 60mg/Kg of 
OPC31260 did not show a significantly higher reduction of tumor size, compared to the 
30mg/Kg dose possibly due to target saturation at the lower dose. While the Tolvaptan dose 
of 120mg/Kg was higher than the doses of 60mg/Kg used in normal humans or to treat PKD 
[68, 70], it should be considered that Tolvaptan treatment is designed to slow kidney 
enlargement over years or decades of treatment time for PKD, a strategy that is quite 
different than relatively short term treatments to stop tumor growth. Tolvaptan treatment 
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could cause side effects including polyuria, thirst or in rare cases, liver toxicity in patients 
[68, 70]. Although OPC31260 was found to have an IC50 value of 1.2μM for V2R in vitro 
in isolated rat kidney plasma membranes [66], in our studies, a dose range of 5–10μM was 
required to significantly inhibit migration and colony formation and cell viability, and 
induce cell cycle arrest of Caki-1 and 786-O cells in vitro. This could be because higher 
doses are required in RCC cells to achieve antitumor efficacy. This observation is typical of 
other repurposed drugs for oncological applications [71, 72].
In our in vitro studies, both OPC31260 and Tolvaptan reduced cell viability and wound 
closure in unstimulated ccRCC cells and reduced tumor growth in vivo. In addition, 
OPC31260 and Tolvaptan also significantly increased tumor cell death by apoptosis, while 
dDVAP treatment reduced apoptosis compared to vehicle treatment in mouse xenograft 
tumors. Although the mechanism by which V2R activity regulates tumor cell survival is 
currently unclear, apoptotic cell death in the V2R antagonist treatment groups could also 
have contributed to the smaller tumor size. Tolvaptan was recently approved by the US FDA, 
based on a recent clinical trial for PKD therapy [73]. Thus, while ectopic expression of V2R 
by ccRCC tumor cells could be an adaptation that gives them a survival and pathogenic 
advantage, it also makes V2R a potentially useful target of inhibition for ccRCC therapy.
V2R is a homeostatic hormone receptor required for sodium and water balance in the body. 
Although our study is the first to show a pathologic role for V2R in ccRCC tumor growth, 
hyponatremia, caused by increased V2R activity, and the syndrome of inappropriate 
secretion of antidiuretic hormone (SIADH) due to ectopic release of vasopressin are known 
to occur in hepatocellular, gastric, head and neck, breast and small‐cell lung cancer patients 
[74, 75]. Moreover, hyponatremia is associated with poorer RCC outcomes and has been 
proposed to be used as a prognostic indicator or predictive factor [76, 77]. Importanty, 
Tolvaptan is routinely used for the treatment of hyponatremia in these patients [78]. This is 
consistent with our data, which suggest that the increased AVP in these cancer patients may 
be the cause for hyponatremia, and could also be promoting tumor growth.
In summary, our studies demonstrate ectopic expression of V2R and AVP in ccRCC. The 
V2R agonist dDAVP increased cell proliferation, angiogenesis and tumor growth, whereas, 
V2R antagonists OPC31260 and Tolvaptan suppress tumor growth by reducing tumor cell 
proliferation, increasing apoptosis and reducing angiogenesis. Although OPC31260 was 
found to be more effective compared to Tolvaptan, the later is an FDA approved drug for the 
treatment of hyponatremia and PKD, and could be repurposed for use in ccRCC therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. V2R expression and cell signaling in human RCC tumors:
(A) Pan-cancer V2R (AVPR2 gene) and (B) AVP gene expression determined from the 
TCGA database. Black arrow depicts levels in Pan-kidney cancer (KIPAN). Other tumor 
types assessed include Adreno Cortical carcinoma (ACC), Bladder (BLCA), Breast 
(BRCA), Colon (COAD), Diffuse Large B Cell Lymphoma (DLBC), Esophageal Carcinoma 
(ESCA), Head and Neck (HNSC), Acute Myeloid Leukemia (LAML), Liver Hepatocellular 
Carcinoma (LIHC), Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma 
(LUSC), Ovarian (OV), Pancreatic Adenocarcinoma (PAAD), Prostate Adenocarcinoma 
(PRAD), Rectum Adenocarcinoma (READ), Sarcoma (SARC), Skin Cutaneous Melanoma 
(SKCM), Thyroid Carcinoma (THCA), Thymoma (THYM). (C) RT-PCR for V2R, AVP and 
β-actin using a cDNA array of human non-malignant control (NM-control) kidney and 
ccRCC tumors. Caki-1 cell and mouse pituitary lysate are used as positive controls 
respectively for V2R and AVP respectively. (D) Immunostaining for V2R in human ccRCC 
tumor or NM-control kidney samples. * represents proximal tubules and arrows point to 
cells showing V2R staining (brown). (E) Pathologist’s scoring of V2R expression in tissue 
microarray. Numbers in the graph represent the number of tissue core samples. (F) The 
percentage of ccRCC tumors with V2R expression in different tumor grades and (G) 
different TNM staging. (H) RTPCR for V2R and β-actin in cultured Caki-1, 786-O and 
ACHN human RCC cell lines. Positive controls 1 and 2 represent cystic epithelial cells from 
human polycystic kidney disease kidneys and 18 h water-deprived mouse kidneys, 
respectively. The HK-2 human proximal tubule cell line is a negative control.
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Figure 2. Effect of V2R antagonists on growth of RCC cell lines:
(A) Cell viability of 786-O, and Caki-1 cells treated with OPC31260 for 48h measured by 
MTT assay. (B) Representative images of clonogenic assays, of Caki-1 and 786-O cell lines 
treated with OPC31260. (C) Quantification of OPC31260-resistant colony formation. 
***P<0.001 vs 0μM OPC31260. (D) Representative histograms and (E) quantification of 
cell cycle stages in 786-O and (F) Caki-1 cells treated with OPC31260 (24h), measured by 
FACS analysis of propidium iodide stained cells. (G) Representative images of wound 
healing assay at 0 and 24h after the scratch was placed on monolayers of Caki-1 and 786-O 
cells in the presence of different doses of OPC31260, and (H) quantitation of their percent 
wound closure. **P<0.01 vs 0μM OPC31260. (I) Cell viability of Caki-1 cells treated with 
dDAVP or Tolvaptan for 48h measured by MTT assay. (J) Percent wound closure of Caki-1 
cells, 24h after the scratch was placed in the presence of dDAVP or Tolvaptan. (K) 
Quantification of cell cycle stages in Caki-1 cells treated with Tolvaptan. (L) Representative 
images for figure K. All error bars represent SD. *P<0.05 **P<0.01 and ***P<0.001 vs 
vehicle or 0μM V2R antagonist. P values by one way ANOVA followed by Dunnett’s 
multiple comparison test for Fig 2A, 2C, and 2H, and two-tailed unpaired student’s t-test 
with Welch’s correction and F test in Fig 2I and 2J.
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Figure 3. The effect of OPC31260 on RCC tumor progression:
(A) Nu/Nu mice were inoculated subcutaneously with Caki-1 cells, and 10 days later were 
treated with vehicle or OPC31260 (30 or 60 mg/Kg) for 28 days. Tumor volume is shown. 
(B) Images of tumors and mice with tumors at sacrifice. (C) Tumor weights at sacrifice. 
*P<0.05, ***P<0.001 vs OPC31260 (30 or 60mg/Kg) in Fig 3A and vs vehicle in Fig 3C, 
(n=8 mice/group). All error bars represent SEM. P values by two way repeated measures of 
ANOVA followed by the Bonferroni test for Fig 3A, and one way ANOVA followed by 
Dunnett’s multiple comparison test for Fig 3B.
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Figure 4. Effect of Tolvaptan or dDAVP treatment on RCC tumor progression:
(A) Nu/Nu mice were inoculated subcutaneously with Caki-1 cells, and 10 days later were 
treated with vehicle, Tolvaptan (120mg/Kg) or dDAVP (1 μg/Kg) daily for 28 days. (A) 
Tumor volumes, (B) tumor weights, and (C) representative images of tumors and mice with 
tumors at sacrifice (n=6 mice/group). *P<0.05, **P<0.01 vs vehicle (n=6 mice/group). All 
error bars represent SEM. P values by two way repeated measures of ANOVA followed by 
the Bonferroni test for Fig 4A and one way ANOVA followed by Dunnett’s multiple 
comparison test for Fig 4B.
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Figure 5. Effect of V2R agonist or antagonists on RCC tumor cell survival and growth:
(A) Ki-67, TUNEL and CD31 staining in tumors of mice treated with vehicle, OPC31260, 
Tolvaptan or dDAVP in tissue sections of tumors from studies in Figures 3 and 4. (B) 
Quantification of Ki-67, (C) TUNEL stained cells and (D) CD31 stained vessels (n=4 
tumors each). (E) Western blot for VEGF and (F) Quantification for VEGF bands by 
densitometry relative to GAPDH. (G) Western blot for VEGF in Caki-1 cells treated with 
dDAVP (1nM), Tolvaptan (50μM) and OPC31260 (25μM) *P<0.05, **P<0.01, ***P<0.001 
vs Vehicle. All error bars represent SEM. P values by two-tailed unpaired student’s t-test 
with Welch’s correction and F test in Fig 5B, 5C, 5D, 5F.
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Figure 6. Effect of V2R agonist and antagonists on angiogenesis in RCC tumors:
(A) Western blot using control kidney or ccRCC tumor tissue lysate (B) Intracellular cAMP 
of ccRCC tumors and control kidney tissue measured by ELISA (n=7 or 8). (C) Western blot 
and (D) quantification of band density in tumors of Vehicle and OPC31260 treatment 
groups. (E) Western blot and (F) quantification of band density in tumors of dDAVP and 
Tolvaptan treatment groups. (G) cAMP levels in Caki-1 cells treated with dDAVP (1nM), 
OPC31260 (25μM) and Tolvaptan (50μM). (n=4 each). (H) Western blot of Caki-1 cells 
treated with dDAVP (1nM) or (I) OPC31260 (25μM), Tolvaptan (50μM) and SR49059 
(10nM). (J) Western blot for V2R in Caki-1 cells transfected with Scrambled-siRNA (Scr-
SIRNA) or V2R-siRNA. (K) In Caki-1 cells transfected with (Scr-SIRNA) or V2R-SiRNA 
and treated with vehicle or OPC31260 (25μM), cell cycle analysis by FACS and (L) 
quantitation of % cells in different cell cycle stages. (n=3) (M) Cell viability by MTT assay 
(n=12) and (N) Percent wound closure by scratch assay (n=12). dDAVP (1nM) was used. 
*P<0.05, **P<0.01, ***P<0.001 vs control or vehicle in B, D, F and G; vs vehicle treated 
Scr-siRNA in L, M and N. All error bars represent SD. P values by by two-tailed unpaired 
student’s t-test with Welch’s correction and F test in Fig 6B, 6D and 6F.
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